Prosecution Insights
Last updated: May 29, 2026

Momenta Pharmaceuticals Inc.

10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
6
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

6
Overdue
0
Due this week
4
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (6)Due ≤ 30 days (4)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (10%)
2
Medium (20%)
0
Easy (0%)
7
Unknown (70%)

Rejection Statute Mix

BucketCases
§101 only1 (10%)
§103 only2 (20%)
No statute on record7 (70%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROONEY, NORA MAUREEN 1 60.5% +23.2%
HADDAD, MAHER M 1 50.4% +54.3%
FAUST, AMBER KATHLEEN 1 62.3% +50.3%
LEONARD, ARTHUR S 1 50.5% +50.7%
GUSTILO, ESTELLA M 1 52.7% +33.9%
D' AMBROSIO, THEA 1 55.6% +56.8%
KIM, YUNSOO 1 65.6% +35.2%
BOWERS, ERIN M 1 54.9% +11.4%
GAO, ASHLEY HARTMAN 1 59.8% +38.9%
RAGHU, GANAPATHIRAM 1 73.7% +26.2%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 4d overdue

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18022069 SIALYLATED GLYCOPROTEINS KIM, YUNSOO 52d overdue
18218996 Sialylated Glycoproteins HADDAD, MAHER M 36d overdue
18258189 ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1 GUSTILO, ESTELLA M 32d overdue
18452346 FCRN ANTIBODIES AND METHODS OF USE THEREOF ROONEY, NORA MAUREEN 30d overdue
18218535 Sialylated Glycoproteins FAUST, AMBER KATHLEEN 19d overdue
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 4d overdue
18022061 HYPERSIALYLATED IMMUNOGLOBULIN BOWERS, ERIN M 8d
17925999 HYPER-SIALYLATED IMMUNOGLOBULIN GAO, ASHLEY HARTMAN 15d

Top Art Units

Art UnitApps
1641 3
1643 1
1631 1
1646 1
1654 1
1653 1
1678 1
1652 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18452346 FCRN ANTIBODIES AND METHODS OF USE THEREOF ROONEY, NORA MAUREEN 1641 Other Final Rejection 30d overdue Pending Aug 18, 2023
18218996 Sialylated Glycoproteins HADDAD, MAHER M 1641 Other Non-Final OA 36d overdue Pending Jul 06, 2023
18218535 Sialylated Glycoproteins FAUST, AMBER KATHLEEN 1643 Other Non-Final OA 19d overdue Pending Jul 05, 2023
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 1631 §101 Non-Final OA 4d overdue Pending Jun 30, 2023
18258189 ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1 GUSTILO, ESTELLA M 1646 Other Non-Final OA 32d overdue Pending Jun 16, 2023
18136803 Sialylated Glycoproteins D' AMBROSIO, THEA 1654 Other Final Rejection 27d Pending Apr 19, 2023
18022069 SIALYLATED GLYCOPROTEINS KIM, YUNSOO 1641 Other Non-Final OA 52d overdue Pending Feb 17, 2023
18022061 HYPERSIALYLATED IMMUNOGLOBULIN BOWERS, ERIN M 1653 Other Non-Final OA 8d Pending Feb 17, 2023
17925999 HYPER-SIALYLATED IMMUNOGLOBULIN GAO, ASHLEY HARTMAN 1678 §103 Final Rejection 15d Pending Nov 17, 2022
17909282 METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN RAGHU, GANAPATHIRAM 1652 §103 Final Rejection 23d Pending Sep 02, 2022

Managing Momenta Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month